% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Klotz:287682,
author = {R. Klotz and A. Ahmed$^*$ and A. Tremmel and C. Büsch and
S. Tenckhoff and C. Doerr-Harim and J. F. Lock and E.-M.
Brede and J. Köninger and J.-H. Schiff and U. A. Wittel and
A. Hötzel and T. Keck and C. Nau and A.-L. Amati and C.
Koch and M. K. Diener and M. A. Weigand and M. W. Büchler
and P. Knebel and J. Larmann},
title = {{T}horacic {E}pidural {A}nalgesia {I}s {N}ot {A}ssociated
{W}ith {I}mproved {S}urvival {A}fter {P}ancreatic {S}urgery:
{L}ong-{T}erm {F}ollow-{U}p of the {R}andomized {C}ontrolled
{PAKMAN} {T}rial.},
journal = {Anesthesia $\&$ analgesia},
volume = {140},
number = {4},
issn = {0003-2999},
address = {[Erscheinungsort nicht ermittelbar]},
publisher = {Ovid},
reportid = {DKFZ-2024-00310},
pages = {798-810},
year = {2025},
note = {140(4):p 798-810, April 2025.},
abstract = {Perioperative thoracic epidural analgesia (EDA) and
patient-controlled intravenous analgesia (PCIA) are common
forms of analgesia after pancreatic surgery. Current
guidelines recommend EDA over PCIA, and evidence suggests
that EDA may improve long-term survival after surgery,
especially in cancer patients. The aim of this study was to
determine whether perioperative EDA is associated with an
improved patient prognosis compared to PCIA in pancreatic
surgery.The PAKMAN trial was an adaptive, pragmatic,
international, multicenter, randomized controlled
superiority trial conducted from June 2015 to October 2017.
Three to five years after index surgery a long-term
follow-up was performed from October 2020 to April 2021.For
long-term follow-up of survival, 109 patients with EDA were
compared to 111 patients with PCIA after partial
pancreatoduodenectomy (PD). Long-term follow-up of quality
of life (QoL) and pain assessment was available for 40
patients with EDA and 45 patients with PCIA (questionnaire
response rate: $94\%).$ Survival analysis revealed that EDA,
when compared to PCIA, was not associated with improved
overall survival (OS, HR, 1.176, $95\%$ HR-CI, 0.809-1.710,
P = .397, n = 220). Likewise, recurrence-free survival did
not differ between groups (HR, 1.116, $95\%$ HR-CI,
0.817-1.664, P = .397, n = 220). OS subgroup analysis
including only patients with malignancies showed no
significant difference between EDA and PCIA (HR, 1.369,
$95\%$ HR-CI, 0.932-2.011, P = .109, n = 179). Similar
long-term effects on QoL and pain severity were observed in
both groups (EDA: n = 40, PCIA: n = 45).Results from this
long-term follow-up of the PAKMAN randomized controlled
trial do not support favoring EDA over PCIA in pancreatic
surgery. Until further evidence is available, EDA and PCIA
should be considered similar regarding long-term survival.},
cin = {D196},
ddc = {610},
cid = {I:(DE-He78)D196-20160331},
pnm = {314 - Immunologie und Krebs (POF4-314)},
pid = {G:(DE-HGF)POF4-314},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:38335141},
doi = {10.1213/ANE.0000000000006812},
url = {https://inrepo02.dkfz.de/record/287682},
}